Research programme: anti-cancer therapeutics - CASI Pharmaceuticals

Drug Profile

Research programme: anti-cancer therapeutics - CASI Pharmaceuticals

Alternative Names: CASI 001; CASI 002

Latest Information Update: 20 Jul 2016

Price : $50

At a glance

  • Originator CASI Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 31 May 2016 CASI Pharmaceuticals announces intention to submit an IND for Cancer in China by 2017
  • 19 Mar 2015 Preclinical trials in Cancer in USA (unspecified route) before March 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top